Recursion Pharmaceuticals, Inc.’s RXRX share price has dipped by 11.85%, which has investors questioning if this is right ...

RXRX's CDK7 inhibitor REC-617 has demonstrated activity, but additional data from the ELUCIDATE trial in various solid tumors ...